人类生长激素 (HGH) 市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

人类生长激素 (HGH) 市场按应用(生长激素缺乏症、特纳综合征、特发性身材矮小、Prader-Willi 综合征和其他应用)、分销渠道(医院和零售药店、在线药店和其他分销渠道)细分和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述部分的价值(以百万美元计)。

市场快照

Human Growth Hormone (HGH) Market Overview
Study Period: 2018-2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.61 %
Human Growth Hormone (HGH) Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

2020 年人类生长激素市场的市场规模为 46.3254 亿美元,预计到 2026 年将达到 75.6774 亿美元,在 2021-2026 年的预测期内,复合年增长率为 8.61%。

根据 Mohamed Hamdy Elkarow 等人发表在 2020 年 11 月内分泌学前沿杂志上的一篇研究文章,生长激素分泌减少的患者构成 COVID-19 严重程度的危险因素,需要注意易感人群的预防措施。

此外,患有 Prader-Willi 综合征的患者应采取额外的预防措施,以尽量减少感染 COVID-19 的风险。此外,Prader-Willi 综合征患者可能不会出现高温等典型症状,他们也可能会出现高于正常的疼痛阈值,这可能会延迟 COVID-19 的诊断。

推动市场增长的主要因素包括重组人类生长激素药物的开发、垂体功能障碍病例的增加以及人类生长激素的超说明书使用增加。

在人类中,当垂体不能合成足够浓度的人类生长激素时,就会导致生长激素缺乏。通过皮下注射施用重组人生长激素来治疗这种缺陷。Prader-Willi 综合征和 Turner 综合征等各种遗传疾病也可能导致生长激素缺乏,导致青春期延迟和低于平均身高。

特纳综合征,也称为先天性卵巢发育不全综合征,发生在女性 X 染色体部分或完全缺失时。崔晓晓等人在 2018 年《难治性与罕见病研究杂志》上发表的一篇研究文章指出,在全球范围内,特纳综合征 (TS) 是一种相对常见的人类染色体畸变类型,发生在 1:2,500 的活产女性中。

人类生长激素有助于刺激再生、繁殖和生长。生长激素使用的增加和对生长激素的认识,有助于管理生长激素缺乏症,正在促进市场增长。

此外,大多数公司都在投资研发,以开发一种副作用较少的生长激素,并将成为一种长效激素疗法。此外,新型重组人类生长激素的快速发展预计将在预测期内推动人类生长激素市场。

报告范围

根据报告的范围,人类生长激素,也称为生长激素,是一种刺激生长、细胞繁殖和细胞再生的肽激素。人类生长激素 (HGH) 市场按应用(生长激素缺乏症、特纳综合征、特发性身材矮小、Prader-Willi 综合征和其他应用)、分销渠道(医院和零售药店、在线药店和其他分销渠道)细分和地理(北美、欧洲、亚太地区、中东和非洲以及南美)。该报告提供了上述部分的价值(以百万美元计)。

By Application
Growth Hormone Deficiency
Turner Syndrome
Idiopathic Short Stature
Prader-Willi Syndrome
Other Applications
By Distribution Channel
Hospitals and Retail Pharmacies
Online Pharmacies
Other Distribution Channels
Geography
North America
United States (By Application and Distribution Channel)
Canada (By Application and Distribution Channel)
Mexico (By Application and Distribution Channel)
Europe
Germany (By Application and Distribution Channel)
United Kingdom (By Application and Distribution Channel)
France (By Application and Distribution Channel)
Italy (By Application and Distribution Channel)
Spain (By Application and Distribution Channel)
Rest of Europe (By Application and Distribution Channel)
Asia-Pacific
China (By Application and Distribution Channel)
Japan (By Application and Distribution Channel)
India (By Application and Distribution Channel)
Australia (By Application and Distribution Channel)
South Korea (By Application and Distribution Channel)
Rest of Asia-Pacific (By Application and Distribution Channel)
Middle-East and Africa
GCC (By Application and Distribution Channel)
South Africa (By Application and Distribution Channel)
Rest of Middle-East and Africa (By Application and Distribution Channel)
South America
Brazil (By Application and Distribution Channel)
Argentina (By Application and Distribution Channel)
Rest of South America (By Application and Distribution Channel)

Report scope can be customized per your requirements. Click here.

主要市场趋势

特纳综合征部分预计将在预测期内占有重要的市场份额

特纳综合征是一种影响女性的罕见染色体疾病。它的特点是其中一条 X 染色体部分或完全缺失。特纳综合征的症状包括颈宽、发际线低或模糊、有高血压倾向、轻微的眼部问题、眼睑下垂和甲状腺功能低下。

患有特纳综合征的人患 COVID-19 病毒严重疾病的风险更高。此外,特纳综合征患者经常患有先天性心脏病,包括患有二尖瓣主动脉瓣。心脏病是一种潜在的疾病,可能导致 COVID-19 引起严重的并发症。

根据 Xiaoxiao Cui 等人的研究文章。特纳综合征 (TS) 发表在 2018 年顽固性和罕见疾病研究中,是一种相对常见的人类染色体畸变类型,发生在 1:2,500 的活产女性中。它在中国非常流行。

由于特纳综合征与许多与心脏、自身免疫性疾病、心理健康问题、听力损失、不孕症和妊娠并发症有关的并发症有关,对涉及生长激素的治疗​​的需求正在增加,这推动了市场的增长。

各种公共和私人组织对特纳综合征的早期诊断和治疗的认识不断提高,预计将推动市场增长。例如,英国特纳综合征支持协会、美国特纳综合征协会和特纳综合征基金会等非营利组织每年 2 月庆祝“特纳综合征宣传月”,并在全国范围内开展宣传该病的宣传活动。 .

此外,增加对特纳综合征 (TS) 有效疗法的研究和开发对市场增长产生了积极影响。例如,根据发表在 2018 年难治性和罕见疾病研究中的研究,特纳综合征 (TS) 的下一代治疗将基于干细胞和再生医学。因此,考虑到上述因素,预计市场将在预测期内出现显着增长。

Human Growth Hormone (HGH) Market Share

预计北美将在预测期内主导市场

推动美国市场增长的主要因素包括不断增加的研发活动、有利的报销政策、已建立的医疗保健基础设施、重要的政府举措以及不断提高的医疗保健意识。

根据 Prader-Willi 研究基金会 2020 年 8 月的登记数据,在 Prader-Willi 综合征患者中,由于美国与 COVID-19 相关的限制,COVID-19 对获得医疗护理和治疗产生了影响。此外,与 COVID-19 相关的限制也对临时获得身体、职业、言语和心理治疗产生了影响。Prader-Willi 综合征相关疗法的使用率下降了 60-80%。

根据 Jessica Bohonowych 等人在 2019 年《基因杂志》上发表的一篇研究文章,Prader-Willi 综合征 (PWS) 是一种罕见的遗传疾病,估计在美国约有 10,000 至 20,000 人患病。

根据美国儿科学会的说法,生长激素缺乏症是一种罕见的疾病,在美国影响不到 3,000 到 10,000 名儿童中的一名。在美国,重组生长激素已广泛用于治疗慢性肾功能不全、生长激素缺乏症 (GHD)、胎龄或宫内发育迟缓、特纳综合征、普拉德-威利综合征和恶病质。

此外,提高对生长激素缺乏症和治疗的认识有望促进市场增长。例如,国际内分泌患者支持组织联盟 (ICOSEP) 每年都会庆祝儿童成长意识日,以传播对生长激素疾病早期诊断和治疗的认识。

在开发有效疗法方面不断增加的研究和开发活动导致管道药物数量的增加。例如,2019 年 10 月,辉瑞公司及其合作伙伴 OPKO Health Inc. 宣布,其在青春期前儿童中使用人类生长激素研究 Somatrogon 的 III 期研究达到了其不劣于每日生长激素的主要终点。因此,由于上述因素,预计北美将在预测期内实现增长。

Human Growth Hormone (HGH) Market Growth Rate By Region

竞争格局

人类生长激素市场适度整合,少数市场参与者控制着重要的市场份额。此外,在开发更有效和长效的人类生长激素亚型方面,有几个积极的合作伙伴关系。一些主要的市场参与者包括 AnkeBio Co. Ltd、Eli Lilly and Company、Ferring BV、Novo Nordisk AS、Ipsen SA、Pfizer Inc.、Genentech Inc. (Roche) 和 Teva Pharmaceutical Industries Ltd.。

Key Market Player Analysis

In February 2021, Pfizer Inc. initiated a Phase III clinical trial to evaluate the efficacy and safety of somatropin in a cohort of Japanese participants with Prader-Willi Syndrome (PWS).

In October 2020, Erasmus Medical Center, in collaboration with Pfizer, Foundation for Prader-Willi Research, and Prader-Willi Fonds, initiated a Phase III clinical trial to assess the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults of 30 years or older with Prader-Willi syndrome.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Development of Recombinant Human Growth Hormone Drugs

      2. 4.2.2 Rise in Pituitary Dysfunction Cases

      3. 4.2.3 Rising Off-label Use of Human Growth Hormones

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects Associated with Human Growth Hormones

      2. 4.3.2 Stringent Regulatory Processes

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Application

      1. 5.1.1 Growth Hormone Deficiency

      2. 5.1.2 Turner Syndrome

      3. 5.1.3 Idiopathic Short Stature

      4. 5.1.4 Prader-Willi Syndrome

      5. 5.1.5 Other Applications

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospitals and Retail Pharmacies

      2. 5.2.2 Online Pharmacies

      3. 5.2.3 Other Distribution Channels

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States (By Application and Distribution Channel)

        2. 5.3.1.2 Canada (By Application and Distribution Channel)

        3. 5.3.1.3 Mexico (By Application and Distribution Channel)

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany (By Application and Distribution Channel)

        2. 5.3.2.2 United Kingdom (By Application and Distribution Channel)

        3. 5.3.2.3 France (By Application and Distribution Channel)

        4. 5.3.2.4 Italy (By Application and Distribution Channel)

        5. 5.3.2.5 Spain (By Application and Distribution Channel)

        6. 5.3.2.6 Rest of Europe (By Application and Distribution Channel)

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China (By Application and Distribution Channel)

        2. 5.3.3.2 Japan (By Application and Distribution Channel)

        3. 5.3.3.3 India (By Application and Distribution Channel)

        4. 5.3.3.4 Australia (By Application and Distribution Channel)

        5. 5.3.3.5 South Korea (By Application and Distribution Channel)

        6. 5.3.3.6 Rest of Asia-Pacific (By Application and Distribution Channel)

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC (By Application and Distribution Channel)

        2. 5.3.4.2 South Africa (By Application and Distribution Channel)

        3. 5.3.4.3 Rest of Middle-East and Africa (By Application and Distribution Channel)

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil (By Application and Distribution Channel)

        2. 5.3.5.2 Argentina (By Application and Distribution Channel)

        3. 5.3.5.3 Rest of South America (By Application and Distribution Channel)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AnkeBio Co. Ltd

      2. 6.1.2 EMD Serono Inc.

      3. 6.1.3 F.Hoffmann-La Roche Ltd

      4. 6.1.4 Ferring BV

      5. 6.1.5 Ipsen SA

      6. 6.1.6 Eli Lilly and Company

      7. 6.1.7 Novo Nordisk AS

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Teva Pharmaceutical Industries Ltd

      10. 6.1.10 Sandoz International GmbH (Novartis AG)

      11. 6.1.11 Strongbridge Biopharma

      12. 6.1.12 GeneScience Pharmaceuticals Co. Ltd

      13. 6.1.13 Sinobioway Hygene Biomedicine Co. Ltd

      14. 6.1.14 Aeterna Zentaris

      15. 6.1.15 LG Life Sciences

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Human Growth Hormone (HGH) Market market is studied from 2018 - 2026.

The Global Human Growth Hormone (HGH) Market is growing at a CAGR of 8.61% over the next 5 years.

The Global Human Growth Hormone (HGH) Market is valued at 4632 Million USD in 2018.

The Global Human Growth Hormone (HGH) Market is valued at 7567 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AnkeBio Co. Ltd, Eli Lilly and Company, Ferring BV, Novo Nordisk AS, Ipsen S.A. are the major companies operating in Global Human Growth Hormone (HGH) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!